{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:25:01Z","timestamp":1787246701776,"version":"build-2736575974"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01809-8","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:49:23Z","timestamp":1780991363000},"page":"3791-3811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Woong","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"4","key":"1809_CR1","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385.","journal-title":"Can Fam Physician"},{"key":"1809_CR2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19144.1","volume":"8","author":"DV Ocampo","year":"2019","unstructured":"Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:F1000 Faculty Rev-1665. https:\/\/doi.org\/10.12688\/f1000research.19144.1.","journal-title":"F1000Res"},{"key":"1809_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"issue":"7","key":"1809_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1346-8138.14338","volume":"45","author":"S Imafuku","year":"2018","unstructured":"Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805\u201311. https:\/\/doi.org\/10.1111\/1346-8138.14338.","journal-title":"J Dermatol"},{"issue":"2","key":"1809_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173\u201392. https:\/\/doi.org\/10.1007\/s40257-020-00578-0.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1809_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628\u201337. https:\/\/doi.org\/10.1111\/bjd.19039.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1809_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1809_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations. Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"Acad Dermatol Venereol"},{"issue":"4","key":"1809_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/jdv.16866","volume":"35","author":"M Nogueira","year":"2021","unstructured":"Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824\u201334. https:\/\/doi.org\/10.1111\/jdv.16866.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1809_CR10","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616\u201326. https:\/\/doi.org\/10.1111\/jdv.14433.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1809_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1172\/JCI39143","volume":"119","author":"EA Miller","year":"2009","unstructured":"Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest. 2009;119(5):1079\u201382.","journal-title":"J Clin Invest"},{"key":"1809_CR12","unstructured":"World Health Organization. Global tuberculosis report 2024. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/data. Accessed 2025 Sep 22."},{"key":"1809_CR13","unstructured":"World Bank Group. Incidence of tuberculosis (per 100,000 people). https:\/\/data.worldbank.org\/indicator\/SH.TBS.INCD. Accessed 2025 Sep 30."},{"issue":"1","key":"1809_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"1809_CR15","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Canada: Ottawa Hospital Research Institute; 2000. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 4 July 2025."},{"key":"1809_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"2","key":"1809_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.abd.2024.08.002","volume":"100","author":"TF Cestari","year":"2025","unstructured":"Cestari TF, Souza CdaS, Azulay-Abulafia L, et al. Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase\u202f3 study with an open-label extension period in Brazil. An Bras Dermatol. 2025;100(2):260\u201371. https:\/\/doi.org\/10.1016\/j.abd.2024.08.002.","journal-title":"An Bras Dermatol"},{"issue":"9","key":"1809_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, et al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160(9):953. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2463.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1809_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9967747","volume":"2023","author":"T Passeron","year":"2023","unstructured":"Passeron T, Carrascosa JM, Warren RB, et al. A phase\u00a0IIIb, multicentre, interventional, randomised, placebo-controlled clinical trial investigating the efficacy and safety of guselkumab for the treatment of nonpustular palmoplantar psoriasis (G-PLUS). Dermatol Ther. 2023;2023(1):9967747. https:\/\/doi.org\/10.1155\/2023\/9967747.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1809_CR20","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1080\/09546634.2021.1914812","volume":"33","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150\u2009mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022;33(4):2085\u201393. https:\/\/doi.org\/10.1080\/09546634.2021.1914812.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1809_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjd.20481","volume":"186","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Eyerich K, Pinter A, et al. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-na\u00efve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2022;186(1):30\u20139. https:\/\/doi.org\/10.1111\/bjd.20481.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1809_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy\u2013assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139. https:\/\/doi.org\/10.1111\/bjd.19341.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1809_CR23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358. https:\/\/doi.org\/10.1111\/bjd.19509.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1809_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358. https:\/\/doi.org\/10.1111\/bjd.18851.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1809_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase\u00a03 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1809_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","volume":"31","author":"LK Ferris","year":"2020","unstructured":"Ferris LK, Ott E, Jiang J, et al. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase\u00a03 ORION study. J Dermatolog Treat. 2020;31(2):152\u20139. https:\/\/doi.org\/10.1080\/09546634.2019.1587145.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1809_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjd.18696","volume":"183","author":"D Tha\u00e7i","year":"2020","unstructured":"Tha\u00e7i D, Pinter A, Sebastian M, et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase\u00a0IIIb trial (POLARIS). Br J Dermatol. 2020;183(2):265\u201375. https:\/\/doi.org\/10.1111\/bjd.18696.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"1809_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase\u00a03, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"10198","key":"1809_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394(10198):576\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3.","journal-title":"Lancet"},{"issue":"8","key":"1809_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the Susta IMM phase\u00a02\/3 trial. J Dermatol. 2019;46(8):686\u201394. https:\/\/doi.org\/10.1111\/1346-8138.14941.","journal-title":"J Dermatol"},{"issue":"1","key":"1809_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase\u00a0III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323. https:\/\/doi.org\/10.1111\/bjd.15750.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1809_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase\u00a03, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053\u201362. https:\/\/doi.org\/10.1111\/1346-8138.14504.","journal-title":"J Dermatol"},{"issue":"10148","key":"1809_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase\u00a03 trials. Lancet. 2018;392(10148):650\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6.","journal-title":"Lancet"},{"issue":"3","key":"1809_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase\u00a0III, double-blind, placebo- and active comparator\u2013controlled VOYAGE\u00a02 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1809_CR35","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1111\/jdv.16460","volume":"34","author":"L Puig","year":"2020","unstructured":"Puig L, Tsai T-F, Bhutani T, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase\u00a03 VOYAGE 1 & VOYAGE\u00a02 trials. Acad Dermatol Venereol. 2020;34(8):1744\u20139. https:\/\/doi.org\/10.1111\/jdv.16460.","journal-title":"Acad Dermatol Venereol"},{"issue":"4","key":"1809_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5\u00a0years of continuous treatment with guselkumab: pooled analyses from the phase\u00a03 VOYAGE 1 and VOYAGE\u00a02 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2021.11.004.","journal-title":"J Am Acad Dermatol"},{"key":"#cr-split#-1809_CR37.1","unstructured":"Puig L, Tsai TF, Bhutani T, et al. Abstract 1765: Safety profile in psoriasis patients with latent tuberculosis treated concomitantly with guselkumab and anti-tuberculosis medications through 5 years in VOYAGE 1 and VOYAGE\u00a02. Milan"},{"key":"#cr-split#-1809_CR37.2","unstructured":"2022. https:\/\/eadv.org\/scientific\/abstract-books\/. Accessed 2025 Nov 10."},{"issue":"2","key":"1809_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, et al. A phase\u00a02 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1501646.","journal-title":"N Engl J Med"},{"issue":"S1","key":"1809_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.19296","volume":"39","author":"S Gerdes","year":"2025","unstructured":"Gerdes S, Hoffmann M, Asadullah K, et al. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: week\u00a0104 results from the non-interventional, prospective, German multicentre PERSIST study. Acad Dermatol Venereol. 2025;39(S1):38\u201349. https:\/\/doi.org\/10.1111\/jdv.19296.","journal-title":"Acad Dermatol Venereol"},{"issue":"3\u20134","key":"1809_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/00325481.2025.2493042","volume":"137","author":"A Demirbas","year":"2025","unstructured":"Demirbas A, Diremsizoglu E, Esen M, Ulutas Demirbas G. Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis. Postgrad Med. 2025;137(3\u20134):299\u2013308. https:\/\/doi.org\/10.1080\/00325481.2025.2493042.","journal-title":"Postgrad Med"},{"issue":"9","key":"1809_CR41","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/ced\/llaf172","volume":"50","author":"E Mortato","year":"2025","unstructured":"Mortato E, Talamonti M, Marcelli L, et al. A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study. Clin Exp Dermatol. 2025;50(9):1786\u201394. https:\/\/doi.org\/10.1093\/ced\/llaf172.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1809_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1346-8138.17255","volume":"51","author":"Y Tada","year":"2024","unstructured":"Tada Y, Sugiura Y, Kamishima M, et al. Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study. J Dermatol. 2024;51(6):779\u201390. https:\/\/doi.org\/10.1111\/1346-8138.17255.","journal-title":"J Dermatol"},{"issue":"6","key":"1809_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/1346-8138.17710","volume":"52","author":"Y Tada","year":"2025","unstructured":"Tada Y, Sugiura Y, Kamishima M, et al. Real-world safety and effectiveness of guselkumab in patients with psoriasis: a post-marketing surveillance study through up to week\u00a052 in Japan. J Dermatol. 2025;52(6):967\u201382. https:\/\/doi.org\/10.1111\/1346-8138.17710.","journal-title":"J Dermatol"},{"key":"1809_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294416","author":"S Wu","year":"2023","unstructured":"Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1294416.","journal-title":"Front Immunol"},{"issue":"1","key":"1809_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.35541\/cjd.20240351","volume":"58","author":"L Jin","year":"2025","unstructured":"Jin L, Qiu Y, Wang W, Kang X, Ding Y. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis. Chin J Dermatol. 2025;58(1):47\u201352. https:\/\/doi.org\/10.35541\/cjd.20240351.","journal-title":"Chin J Dermatol"},{"key":"1809_CR46","unstructured":"Brufau Cochs M, Canal-Garcia E, Del Alc\u00e1zar E, et al. Real-life evaluation of risankizumab in treatment-na\u00efVe psoriasis patients: safety and effectiveness in a 2-year multicentric retrospective study. Poster presented at European Academy of Dermatology & Venereology Congress. 2024 Sep 25; Amsterdam."},{"issue":"8","key":"1809_CR47","doi-asserted-by":"publisher","first-page":"632","DOI":"10.36849\/JDD.7486","volume":"23","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of guselkumab in moderate-to-severe plaque psoriasis: a 104-week retrospective single-center study. J Drugs Dermatol. 2024;23(8):632\u20139. https:\/\/doi.org\/10.36849\/JDD.7486.","journal-title":"J Drugs Dermatol"},{"issue":"17","key":"1809_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175175","volume":"13","author":"L Marcelli","year":"2024","unstructured":"Marcelli L, Belcastro A, Talamonti M, et al. Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: a long-term real-life experience. JCM. 2024;13(17):5175. https:\/\/doi.org\/10.3390\/jcm13175175.","journal-title":"JCM"},{"issue":"2","key":"1809_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","volume":"25","author":"T Torres","year":"2024","unstructured":"Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25(2):333\u201342. https:\/\/doi.org\/10.1007\/s40257-024-00845-4.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1809_CR50","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/jdv.18913","volume":"37","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study \u2013 IL PSO (ITALIAN LANDSCAPE PSORIASIS). Acad Dermatol Venereol. 2023;37(5):1017\u201327. https:\/\/doi.org\/10.1111\/jdv.18913.","journal-title":"Acad Dermatol Venereol"},{"issue":"6","key":"1809_CR51","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s13555-025-01416-z","volume":"15","author":"M Valenti","year":"2025","unstructured":"Valenti M, Ibba L, Di Giulio S, et al. Optimizing tildrakizumab dosing in psoriasis: a 52-week multicenter retrospective study comparing 100\u00a0mg and 200\u00a0mg\u2014IL PSO (Italian landscape psoriasis). Dermatol Ther (Heidelb). 2025;15(6):1427\u201340. https:\/\/doi.org\/10.1007\/s13555-025-01416-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1809_CR52","doi-asserted-by":"publisher","first-page":"754","DOI":"10.36849\/jdd.7471","volume":"22","author":"J Heim","year":"2023","unstructured":"Heim J, Vasquez JG, Schenkel B, Bhatia N. Real-world effectiveness and safety of tildrakizumab in patients with moderate-to-severe psoriasis: week\u00a028 interim analysis of a phase\u00a04 study. J Drugs Dermatol. 2023;22(8):754\u201360. https:\/\/doi.org\/10.36849\/jdd.7471.","journal-title":"J Drugs Dermatol"},{"key":"1809_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1285972","volume":"10","author":"J Zheng","year":"2023","unstructured":"Zheng J, Chen W, Yi X, Yu N, Ding Y, Gao Y. Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis. Front Med. 2023;10:1285972. https:\/\/doi.org\/10.3389\/fmed.2023.1285972.","journal-title":"Front Med"},{"issue":"2","key":"1809_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/ds.ds_18_22","volume":"40","author":"YW Huang","year":"2022","unstructured":"Huang YW, Tsai TF. The seroconversion rate of QuantiFERON-TB Gold In-Tube Test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies. Dermatol Sin. 2022;40(2):94\u20139. https:\/\/doi.org\/10.4103\/ds.ds_18_22.","journal-title":"Dermatol Sin"},{"key":"1809_CR55","doi-asserted-by":"publisher","unstructured":"Zhuang J, Li J, Zhong Y, et al. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: a prospective real-life study on the Chinese population. Dermatol Ther. 2021;34(5):e15054. https:\/\/doi.org\/10.1111\/dth.15054.","DOI":"10.1111\/dth.15054"},{"key":"1809_CR56","doi-asserted-by":"publisher","unstructured":"Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964. https:\/\/doi.org\/10.1111\/dth.13964","DOI":"10.1111\/dth.13964"},{"issue":"3","key":"1809_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase\u00a0IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359\u201369. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220991.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1809_CR58","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3899\/jrheum.220928","volume":"50","author":"P Rahman","year":"2023","unstructured":"Rahman P, Boehncke WH, Mease PJ, et al. Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol. 2023;50(6):769\u201380. https:\/\/doi.org\/10.3899\/jrheum.220928.","journal-title":"J Rheumatol"},{"issue":"2","key":"1809_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE\u00a01 trial. Ann Rheum Dis. 2022;81(2):225\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221019.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1809_CR60","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","volume":"62","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE\u00a01 study. Rheumatology. 2023;62(6):2113\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/keac607.","journal-title":"Rheumatology"},{"issue":"3","key":"1809_CR61","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","volume":"11","author":"LE Kristensen","year":"2024","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the phase\u00a03 KEEPsAKE1 randomized clinical trial. Rheumatol Ther. 2024;11(3):617\u201332. https:\/\/doi.org\/10.1007\/s40744-024-00654-5.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"1809_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, Van Den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE\u00a02 trial. Ann Rheum Dis. 2022;81(3):351\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221048.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1809_CR63","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","volume":"62","author":"A \u00d6st\u00f6r","year":"2023","unstructured":"\u00d6st\u00f6r A, Van Den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE\u00a02 study. Rheumatology. 2023;62(6):2122\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keac605.","journal-title":"Rheumatology"},{"issue":"3","key":"1809_CR64","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s40744-024-00657-2","volume":"11","author":"A \u00d6st\u00f6r","year":"2024","unstructured":"\u00d6st\u00f6r A, Van Den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE\u00a02 randomized clinical trial. Rheumatol Ther. 2024;11(3):633\u201348. https:\/\/doi.org\/10.1007\/s40744-024-00657-2.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"1809_CR65","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","volume":"9","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Kellner H, Morita A, et al. Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase\u00a02 randomized trial. Rheumatol Ther. 2022;9(5):1361\u201375. https:\/\/doi.org\/10.1007\/s40744-022-00474-5.","journal-title":"Rheumatol Ther"},{"issue":"10230","key":"1809_CR66","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395(10230):1115\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8.","journal-title":"Lancet"},{"issue":"12","key":"1809_CR67","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3899\/jrheum.201532","volume":"48","author":"P Rahman","year":"2021","unstructured":"Rahman P, Ritchlin CT, Helliwell PS, et al. Pooled safety results through 1\u00a0year of 2 phase\u00a0III trials of guselkumab in patients with psoriatic arthritis. J Rheumatol. 2021;48(12):1815\u201323. https:\/\/doi.org\/10.3899\/jrheum.201532.","journal-title":"J Rheumatol"},{"issue":"6","key":"1809_CR68","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40744-024-00713-x","volume":"11","author":"P Mease","year":"2024","unstructured":"Mease P, Korotaeva T, Shesternya P, et al. Guselkumab in biologic-na\u00efve patients with active psoriatic arthritis in Russia: a post hoc analysis of the DISCOVER-1 and -2 randomized clinical trials. Rheumatol Ther. 2024;11(6):1551\u201367. https:\/\/doi.org\/10.1007\/s40744-024-00713-x.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1809_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1\u00a0year results of a phase\u00a0III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7(1):e001457. https:\/\/doi.org\/10.1136\/rmdopen-2020-001457.","journal-title":"RMD Open"},{"issue":"3","key":"1809_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr2.11523","volume":"5","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Deodhar A, Boehncke W, et al. Multidomain efficacy and safety of guselkumab through 1\u00a0year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase\u00a03, randomized, placebo-controlled DISCOVER-1 study. ACR Open Rheumatol. 2023;5(3):149\u201364. https:\/\/doi.org\/10.1002\/acr2.11523.","journal-title":"ACR Open Rheumatol"},{"issue":"10230","key":"1809_CR71","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395(10230):1126\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","journal-title":"Lancet"},{"issue":"4","key":"1809_CR72","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604\u201316. https:\/\/doi.org\/10.1002\/art.41553.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1809_CR73","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385. https:\/\/doi.org\/10.1002\/art.42010.","journal-title":"Arthritis Rheumatol"},{"issue":"10136","key":"1809_CR74","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","volume":"391","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase\u00a02 study. Lancet. 2018;391(10136):2213\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)30952-8.","journal-title":"Lancet"},{"issue":"6","key":"1809_CR75","doi-asserted-by":"publisher","first-page":"410","DOI":"10.12144\/zgmfskin202506410","volume":"41","author":"Q Wu","year":"2025","unstructured":"Wu Q, Bao J, Sun Y, Tao Y. [Evaluation of the efficacy and safety of tiriguzumab in the treatment of 32 patients with moderate to severe plaque psoriasis]. Chin J Lepr Skin Dis. 2025;41(6):410\u20135. https:\/\/doi.org\/10.12144\/zgmfskin202506410.","journal-title":"Chin J Lepr Skin Dis"},{"key":"1809_CR76","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42081","volume":"105","author":"J Li","year":"2025","unstructured":"Li J, Xiang X, Wang Z, Miao C, Chen Y, Xu Z. Safety of interleukin inhibitors in psoriatic patients with latent tuberculosis infection without chemoprophylaxis: a systematic review. Acta Derm Venereol. 2025;105:adv42081\u2013adv42081. https:\/\/doi.org\/10.2340\/actadv.v105.42081.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1809_CR77","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"},{"issue":"25","key":"1809_CR78","doi-asserted-by":"publisher","first-page":"03232","DOI":"10.1016\/j.jaad.2025.11.033","volume":"S0190\u20139622","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Strober BE, Eakin GS, et al. Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. J Am Acad Dermatol. 2025;S0190\u20139622(25):03232\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2025.11.033.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1809_CR79","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.20287","volume":"39","author":"T Torres","year":"2025","unstructured":"Torres T, Brembilla NC, Langley RG, et al. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: recommendations from a SPIN-FRT expert consensus. J Eur Acad Dermatol Venereol. 2025;39(1):52\u201369. https:\/\/doi.org\/10.1111\/jdv.20287.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1809_CR80","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0040-2017","volume":"5","author":"TE Dobbs","year":"2017","unstructured":"Dobbs TE, Webb RM. Chemotherapy of tuberculosis. Microbiol Spectr. 2017;5(2):5.2.23. https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0040-2017.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"1809_CR81","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/cid\/ciy544","volume":"68","author":"RMGJ Houben","year":"2019","unstructured":"Houben RMGJ, Lalli M, Kranzer K, Menzies NA, Schumacher SG, Dowdy DW. What if they don\u2019t have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis. Clin Infect Dis. 2019;68(1):150\u20136. https:\/\/doi.org\/10.1093\/cid\/ciy544.","journal-title":"Clin Infect Dis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01809-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:10Z","timestamp":1787243410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01809-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01809-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hidehisa Saeki received lecture fees from Janssen Pharma, AbbVie, and Sun Pharma. Gang Wang has served as a scientific advisor and\/or speaker for AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, Pfizer, and Sanofi. Chia-Ling Chang is an employee of Johnson & Johnson. Sang Woon Youn has participated as an investigator in clinical trials sponsored by Johnson & Johnson.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}